We, at OmniActive, invest over 10 per cent of the total outlay into R&D
Express Pharma
DECEMBER 2, 2024
This enables us to optimise dosages in our final products, enhancing both bioavailability and patient safety. At OmniActive, the emphasis is given to quality and efficacy through scientific validation, transparent communication, and credible endorsements.
Let's personalize your content